CA2505964A1 - Pharmaceutical compositions and dosage forms of thalidomide - Google Patents
Pharmaceutical compositions and dosage forms of thalidomide Download PDFInfo
- Publication number
- CA2505964A1 CA2505964A1 CA002505964A CA2505964A CA2505964A1 CA 2505964 A1 CA2505964 A1 CA 2505964A1 CA 002505964 A CA002505964 A CA 002505964A CA 2505964 A CA2505964 A CA 2505964A CA 2505964 A1 CA2505964 A1 CA 2505964A1
- Authority
- CA
- Canada
- Prior art keywords
- dosage forms
- thalidomide
- pharmaceutical compositions
- disclosed
- clathrates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960003433 thalidomide Drugs 0.000 title abstract 2
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010024229 Leprosy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000306 sarcoidosis Diseases 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Pharmaceutical compositions and single unit dosage forms of thalidomide and pharmaceutically acceptable prodrugs, salts, solvates, hydrates, or clathrates are disclosed. Also disclosed are methods of treating and preventing diseases and conditions such as, but not limited to, leprosy, chronic graft-vs-host disease, rheumatoid arthritis, sarcoidosis, an inflammatory condition, inflammatory bowel disease, and cancer using the novel dosage forms disclosed herein.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42601602P | 2002-11-14 | 2002-11-14 | |
US60/426,016 | 2002-11-14 | ||
PCT/US2003/036620 WO2004045579A2 (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2505964A1 true CA2505964A1 (en) | 2004-06-03 |
CA2505964C CA2505964C (en) | 2009-07-28 |
Family
ID=32326306
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002505964A Expired - Lifetime CA2505964C (en) | 2002-11-14 | 2003-11-13 | Pharmaceutical compositions and dosage forms of thalidomide |
Country Status (19)
Country | Link |
---|---|
US (1) | US7230012B2 (en) |
EP (2) | EP2277512A3 (en) |
JP (2) | JP5269280B2 (en) |
KR (1) | KR100671366B1 (en) |
CN (2) | CN1738607B (en) |
AU (2) | AU2003290982C1 (en) |
BR (1) | BR0316240A (en) |
CA (1) | CA2505964C (en) |
DK (1) | DK1562556T3 (en) |
ES (1) | ES2403142T3 (en) |
HK (1) | HK1088543A1 (en) |
IL (1) | IL168585A (en) |
MX (1) | MXPA05005162A (en) |
NZ (1) | NZ540545A (en) |
PT (1) | PT1562556E (en) |
SI (1) | SI1562556T1 (en) |
TW (2) | TWI359659B (en) |
WO (1) | WO2004045579A2 (en) |
ZA (1) | ZA200503927B (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
US7838029B1 (en) | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
US20100009928A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
DK2574341T3 (en) | 2004-03-29 | 2017-06-26 | Univ South Florida | Effective treatment of tumors and cancer with triciribin phosphate |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
US20110008327A1 (en) * | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100173864A1 (en) * | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
US7534381B2 (en) * | 2005-09-14 | 2009-05-19 | Isp Investments Inc. | Process and apparatus for forming agglomerates of a powder composition of an active and binder |
CN1870631B (en) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | Gate control method of media gateway |
EP2054040B1 (en) * | 2006-08-16 | 2011-03-30 | Novartis AG | Method for making solid dispersions of midostaurin |
CN103816127A (en) * | 2006-11-10 | 2014-05-28 | 阿尔法普托斯有限公司 | Oral dosage form comprising tri-substituted glycerol compounds |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
RU2479307C1 (en) | 2009-05-19 | 2013-04-20 | Селджин Корпорейшн | Formulation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione |
KR101369936B1 (en) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | Pharmaceutical composition for treating lupus nephritis comprising thalidomide |
JP5087182B1 (en) | 2012-06-13 | 2012-11-28 | クリニプロ株式会社 | Method for producing inhalable powder |
AU2015210999A1 (en) | 2014-01-29 | 2016-07-21 | Otsuka Pharmaceutical Co., Ltd. | Device-based risk management of a therapeutic |
CN106137986B (en) * | 2015-03-09 | 2019-04-16 | 常州制药厂有限公司 | A kind of Thalidomide piece and preparation method thereof |
CN106138052B (en) * | 2015-04-16 | 2020-02-21 | 欣凯医药化工中间体(上海)有限公司 | Thalidomide preparation and preparation method thereof |
EP3691682A1 (en) | 2017-09-14 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
WO2019099868A2 (en) | 2017-11-16 | 2019-05-23 | C4 Therapeutics, Inc. | Degraders and degrons for targeted protein degradation |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
KR20210018199A (en) | 2018-03-26 | 2021-02-17 | 씨4 테라퓨틱스, 인코포레이티드 | Cerevlon binder for decomposition of Ikaros |
EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | Spirocyclic compounds |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
KR20200054046A (en) | 2018-11-09 | 2020-05-19 | 한국화학연구원 | Novel piperidine-2,6-dione derivatives and use thereof |
CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
WO2020181232A1 (en) | 2019-03-06 | 2020-09-10 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
KR20230068335A (en) | 2021-11-09 | 2023-05-17 | 한국화학연구원 | Glutarimide moiety based isoindolinone derivatives and use thereof |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
US6114355A (en) * | 1993-03-01 | 2000-09-05 | D'amato; Robert | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5405855A (en) * | 1993-12-23 | 1995-04-11 | Andrulis Pharmaceuticals Corp. | Treatment of insulin resistant diabetes with thalidomine |
US5434170A (en) * | 1993-12-23 | 1995-07-18 | Andrulis Pharmaceuticals Corp. | Method for treating neurocognitive disorders |
US6001828A (en) * | 1995-06-05 | 1999-12-14 | Andrulis, Jr.; Peter | Use of tumor factor inhibitors together with antiviral agents and therapeutic compositions thereof against HIV infection |
US5731325A (en) * | 1995-06-06 | 1998-03-24 | Andrulis Pharmaceuticals Corp. | Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents |
US5643915A (en) * | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
DE69738935D1 (en) * | 1996-11-05 | 2008-10-02 | Childrens Medical Center | Compositions containing thalidomide and dexamethasone for the treatment of cancer |
CA2319872C (en) * | 2000-02-02 | 2012-06-19 | Chun-Ying Huang | Pharmaceutical composition for the treatment of hepatocellular carcinoma |
NZ521937A (en) * | 2000-03-31 | 2004-08-27 | Celgene Corp | Inhibition of cyclooxygenase-2 activity |
PT1286671E (en) * | 2000-05-15 | 2006-08-31 | Univ Arkansas | COMPOSITIONS FOR THE TREATMENT OF CANCER COLORRECTALQUE UNDERSTAND TALIDOMIDA AND IRINOTECAN |
AU2003222034A1 (en) * | 2002-03-20 | 2003-10-08 | Celgene Corporation | (-)-2-(1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl)-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7230012B2 (en) * | 2002-11-14 | 2007-06-12 | Celgene Corporation | Pharmaceutical compositions and dosage forms of thalidomide |
-
2003
- 2003-06-30 US US10/608,077 patent/US7230012B2/en not_active Expired - Lifetime
- 2003-11-13 DK DK03783567.5T patent/DK1562556T3/en active
- 2003-11-13 WO PCT/US2003/036620 patent/WO2004045579A2/en active Application Filing
- 2003-11-13 SI SI200332255T patent/SI1562556T1/en unknown
- 2003-11-13 KR KR1020057008631A patent/KR100671366B1/en active IP Right Grant
- 2003-11-13 AU AU2003290982A patent/AU2003290982C1/en not_active Expired
- 2003-11-13 MX MXPA05005162A patent/MXPA05005162A/en active IP Right Grant
- 2003-11-13 JP JP2004553785A patent/JP5269280B2/en not_active Expired - Lifetime
- 2003-11-13 NZ NZ540545A patent/NZ540545A/en not_active IP Right Cessation
- 2003-11-13 BR BR0316240-0A patent/BR0316240A/en not_active IP Right Cessation
- 2003-11-13 CN CN200380108803.9A patent/CN1738607B/en not_active Expired - Fee Related
- 2003-11-13 EP EP10175930A patent/EP2277512A3/en not_active Withdrawn
- 2003-11-13 CA CA002505964A patent/CA2505964C/en not_active Expired - Lifetime
- 2003-11-13 EP EP03783567A patent/EP1562556B1/en not_active Expired - Lifetime
- 2003-11-13 ES ES03783567T patent/ES2403142T3/en not_active Expired - Lifetime
- 2003-11-13 CN CN201010115035A patent/CN101816626A/en active Pending
- 2003-11-13 PT PT37835675T patent/PT1562556E/en unknown
- 2003-11-14 TW TW092132008A patent/TWI359659B/en not_active IP Right Cessation
- 2003-11-14 TW TW096113473A patent/TWI377062B/en not_active IP Right Cessation
-
2005
- 2005-05-15 IL IL168585A patent/IL168585A/en active IP Right Grant
- 2005-05-16 ZA ZA200503927A patent/ZA200503927B/en unknown
-
2006
- 2006-08-15 HK HK06109062.8A patent/HK1088543A1/en not_active IP Right Cessation
-
2009
- 2009-05-15 JP JP2009119084A patent/JP4927905B2/en not_active Expired - Fee Related
-
2010
- 2010-05-13 AU AU2010201931A patent/AU2010201931A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2505964A1 (en) | Pharmaceutical compositions and dosage forms of thalidomide | |
MXPA04003439A (en) | 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists. | |
MXPA05010958A (en) | Indazole derivatives as jnk inhibitors. | |
MXPA04006555A (en) | 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists. | |
MY148125A (en) | Compounds | |
AU3664401A (en) | Platelet adp receptor inhibitors | |
EP2260835A3 (en) | Composition for proteasome inhibition | |
HK1062677A1 (en) | 17Beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
EP1734041A3 (en) | Platelet ADP receptor inhibitors | |
HRP20070020T3 (en) | 1-(2h-pyrazol-3-yl)-3- 4-[1-(benzoyl)-piperidin-4-ylmethyl]-phenyl -urea derivatives and related compounds as inhibitors of p38 kinase and/or tnf inhibitors for the treatment of inflammations | |
NO20050851L (en) | Caspase Inhibitors and Uses thereof | |
IL169439A0 (en) | Fluoroalkoxy-substituted 1,3 - dihydro-isoindolyl compounds and their pharmaceutical uses | |
TW200736196A (en) | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | |
WO2001035950A3 (en) | Benzamide therapeutics and methods for treating inflammatory bowel disease | |
CY1108625T1 (en) | PHARMACEUTICAL COMPOSITIONS FOR ADMINISTRATION FROM US ORAL OR PRODUCERS | |
WO2003053359A3 (en) | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | |
MX2008001606A (en) | Substituted piperazines as metabotropic glutamate receptor antagonists. | |
WO2003065987A3 (en) | Granzyme b inhibitors | |
RS20050470A (en) | Solid drug for oral use | |
WO2003106450A8 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
NO20071399L (en) | VLA-4 antagonists | |
MXPA05012705A (en) | A pharmaceutical composition comprising a p2x7. | |
UA92009C2 (en) | 4-PHENYL-5-0X0-l,4,5,6,7,8-HEXAHYDR0QЛIN0LINE DERIVATIVES AS MEDICAMENTS FOR THE TREATMENT OF INFERTILITY | |
MX2008001608A (en) | Acetylenic piperazines as metabotropic glutamate receptor antagonists. | |
WO2008005352A3 (en) | Solid dose formulations of a thrombin receptor antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20231114 |